Pfizer Eyes Three Oncology Biosimilar Launches In 2019 As Sterile Injectables Problems Persist
Pfizer’s long-standing sterile injectable supply and manufacturing issues pummelled respective sales in the US in 2018. But the US-based multinational is eyeing a string of oncology biosimilar launches in 2019, which could see biosimilar sales tick past US$1 billion.